Esters-buliding-blocks

On March 20, 2019, Kishimoto, Satoshi; Nakashimada, Yuichi; Yokota, Riri; Hatanaka, Takaaki; Adachi, Motoyasu; Ito, Yuji published an article.Safety of Bis(2,5-dioxopyrrolidin-1-yl) glutarate The title of the article was Site-Specific Chemical Conjugation of Antibodies by Using Affinity Peptide for the Development of Therapeutic Antibody Format. And the article contained the following:

Artificially modified IgG mols. are increasingly utilized in industrial and clin. applications. In the present study, the method of chem. conjugation by affinity peptide (CCAP) for site-specific chem. modification has been developed by using a peptide that bound with high affinity to human IgG-Fc. This method enabled a rapid modification of a specific residue (Lys248 on Fc) in a one-step reaction under mild condition to form a stable amide bond between the peptide and Fc. The monovalent peptide-IgG conjugate not only maintained complete antigen binding but also bound to Fc receptors (FcRn, FcγRI, and FcγRIIIa), indicating that it is a suitable conjugate form that can be further developed into highly functional antibody therapeutics. CCAP was applied for the preparation of an antibody-drug conjugate and a bispecific antibody to demonstrate the usefulness of this method. The experimental process involved the reaction of Bis(2,5-dioxopyrrolidin-1-yl) glutarate(cas: 79642-50-5).Safety of Bis(2,5-dioxopyrrolidin-1-yl) glutarate

The Article related to igg fc heavy chain peptide conjugation drug conjugate bispecific, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Safety of Bis(2,5-dioxopyrrolidin-1-yl) glutarate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On July 22, 2021, Tu, Yalin; Sun, Yameng; Qiao, Shuang; Luo, Yao; Liu, Panpan; Jiang, Zhong-Xing; Hu, Yumin; Wang, Zifeng; Huang, Peng; Wen, Shijun published an article.Application of 882518-89-0 The title of the article was Design, Synthesis, and Evaluation of VHL-Based EZH2 Degraders to Enhance Therapeutic Activity against Lymphoma. And the article contained the following:

Traditional EZH2 inhibitors are developed to suppress the enzymic methylation activity, and they may have therapeutic limitations due to the nonenzymic functions of EZH2 in cancer development. Here, we report proteolysis-target chimera (PROTAC)-based EZH2 degraders to target the whole EZH2 in lymphoma. Two series of EZH2 degraders were designed and synthesized to hijack E3 ligase systems containing either von Hippel-Lindau (VHL) or cereblon (CRBN), and some VHL-based compounds were able to mediate EZH2 degradation Two best degraders, YM181 (I) and YM281 (II), induced robust cell viability inhibition in diffuse large B-cell lymphoma (DLBCL) and other subtypes of lymphomas, outperforming a clin. used EZH2 inhibitor EPZ6438 (tazemetostat) that was only effective against DLBCL. The EZH2 degraders displayed promising antitumor activities in lymphoma xenografts and patient-derived primary lymphoma cells. Our study demonstrates that EZH2 degraders have better therapeutic activity than EZH2 inhibitors, which may provide a potential anticancer strategy to treat lymphoma. The experimental process involved the reaction of tert-Butyl 2-(2-(2-(tosyloxy)ethoxy)ethoxy)acetate(cas: 882518-89-0).Application of 882518-89-0

The Article related to lymphoma ezh2 inhibitors degraders vhl crbn ym181 ym281 antitumor, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Application of 882518-89-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On January 29, 2004, Bergnes, Gustave; Smith, Whitney W.; Yao, Bing; Morgans, David J., Jr.; MacDonald, Andrew published a patent.COA of Formula: C10H19NO4 The title of the patent was Preparation of of quinazolinone-like derivatives to treat cellular proliferative diseases. And the patent contained the following:

The invention relates to quinazolinone-like derivatives that are inhibitors of the mitotic kinesin KSP and are useful in the treatment of cellular proliferative diseases, for example cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders and inflammation. Preparation of 3-Benzyl-7-chloro-2-(3-benzyl-2-oxohexahydropyrimidin-4-yl)-3H-quinazolin-4-one is included. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).COA of Formula: C10H19NO4

The Article related to quinazolinone derivative preparation proliferative disease kinesin, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.COA of Formula: C10H19NO4

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On January 23, 2020, Wang, Lei; Fang, Kun; Cheng, Junfei; Li, Yu; Huang, Yahui; Chen, Shuqiang; Dong, Guoqiang; Wu, Shanchao; Sheng, Chunquan published an article.Name: Methyl N-Methylanthranilate The title of the article was Scaffold Hopping of Natural Product Evodiamine: Discovery of a Novel Antitumor Scaffold with Excellent Potency against Colon Cancer. And the article contained the following:

Inspired by the natural product evodiamine, a novel antitumor indolopyrazinoquinazolinone scaffold was designed by scaffold hopping. Structure-activity relationship studies led to the discovery of compound 15j, which shows low nanomolar inhibitory activity against the HCT116 cell line. Further antitumor mechanism studies indicated that compound 15j acted by the dual inhibition of topoisomerase 1 and tubulin and induced apoptosis with G2 cell-cycle arrest. The quaternary ammonium salt of compound 15j (compound 15js) exhibited excellent in vivo antitumor activity (TGI = 66.6%) in the HCT116 xenograft model with low toxicity. Indolopyrazinoquinazolinone derivatives represent promising multitargeting antitumor leads for the development of novel antitumor agents. The experimental process involved the reaction of Methyl N-Methylanthranilate(cas: 85-91-6).Name: Methyl N-Methylanthranilate

The Article related to colon cancer antitumor agents sar topoisomerase tubulin scaffold apoptosis, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Name: Methyl N-Methylanthranilate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On July 31, 2019, Knewtson, Kelsey E.; Perera, Chamani; Hymel, David; Gao, Zhe; Lee, Molly M.; Peterson, Blake R. published an article.Computed Properties of 79642-50-5 The title of the article was Antibody-Drug Conjugate that Exhibits Synergistic Cytotoxicity with an Endosome-Disruptive Peptide. And the article contained the following:

Antibody-drug conjugates are an important class of cancer therapeutics. These agents generally bind a specific cell surface receptor, undergo receptor-mediated endocytosis, and enter the endosomal-lysosomal system, where the environment in these organelles facilitates the release of a membrane-permeable cytotoxin. By using a membrane-impermeable cytotoxin, we describe here a method that allows the cytotoxicity of an antibody conjugate to be triggered by co-administration with an endosome-disruptive peptide that exhibits low toxicity. This approach was validated by conjugation of an anionic derivative of the tubulin-binding cytotoxin colchinol Me ether to lysine residues of the HER2-targeting antibody trastuzumab (Herceptin) via a disulfide. When this antibody binds HER2 on SKBR3 breast cancer cells and undergoes endocytosis, the membrane-impermeable cytotoxin is released, but it becomes trapped in endosomes, resulting in relatively low cytotoxicity (IC50 > 1μM). However, co-administration with an essentially nontoxic (IC50 > 10μM) cholesterol-linked endosome-disruptive peptide promotes the release of this small mol. into the cytoplasm, conferring subnanomolar cytotoxic potency (IC50 = 0.11 ± 0.07 nM). Studies of a structurally related fluorophore conjugate revealed that the endosome-disruptive peptide does not substantially enhance cleavage of the disulfide (t1/2 = 8 ± 2 h) within endosomes, suggesting that the mechanism of endosomal escape involves the efflux of some small mols. without facilitating substantial influx of reduced glutathione. The experimental process involved the reaction of Bis(2,5-dioxopyrrolidin-1-yl) glutarate(cas: 79642-50-5).Computed Properties of 79642-50-5

The Article related to cancer antibody drug conjugate synergistic cytotoxicity endosome disruptive peptide, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Computed Properties of 79642-50-5

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Srinivas, Avula; Karthik, Pulluri; Sunitha, Malladi; Reddy, Koduri Vasumathi published an article in 2019, the title of the article was Microwave-assisted synthesis and anticancer activity of triazolyl thiazolidine derivatives of pyrene.Synthetic Route of 2873-29-2 And the article contains the following content:

In a one pot procedure a series of (R)-2-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-3,6-dihydro- 2H-pyran-2-yl)-3-phenylthiazolidin-4-ones 9a-g and 2-((2R)-2-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol- 4-yl)methoxy)-3,6-dihydro-2H-pyran-2-yl)-4-oxo-3-phenylthiazolidin-5-yl)acetic acids 10a-g was prepared by condensation of (2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-3,6-dihydro-2H-pyran-2-carbaldehyde with mercapto acids and primary amines in the presence of ZnCl2 under both microwave irradiation and conventional heating conditions. Characterization of new compounds has been done by means of IR, NMR, MS and elemental anal. The cytotoxicity was assessed against a panel of four different human tumor cell lines: A549 derived from human alveolar adenocarcinoma epithelial cells (ATCC NumberCCL-185), Hela derived from human cervical cancer cells (ATCC NumberCCL-2), MDA-MB-231 derived from human breast adenocarcinoma cells (ATCC NumberHTB22) and HEK 293 (normal human embryonic kidney cell line) using the MTT assays. Among the tested compounds 9e and 10e showed the most potent activity against MCF-7 breast cancer cell line with IC50 values of 1.91 and 1.95μM, whereas 9b, 10b, 9g and 10g showed promising activity against MDA-MB-231 and Hela cell lines with IC50 values of 5.84, 5.74, 7.89 and 7.65μM, resp. The experimental process involved the reaction of (2R,3S,4R)-2-(Acetoxymethyl)-3,4-dihydro-2H-pyran-3,4-diyl diacetate(cas: 2873-29-2).Synthetic Route of 2873-29-2

The Article related to breast adenocarcinoma cervical cancer microwave anticancer pyrene triazolyl thiazolidine, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Synthetic Route of 2873-29-2

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Rosowsky, Andre; Forsch, Ronald; Uren, Jack; Wick, Michael published an article in 1981, the title of the article was Methotrexate analogs. 14. Synthesis of new γ-substituted derivatives as dihydrofolate reductase inhibitors and potential anticancer agents.Recommanded Product: (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate And the article contains the following content:

The γ-tert-butyll ester (I) [79640-76-9], γ-hydrazide (II) [79640-75-8], γ-butylamide (III) [79640-74-7], and γ-benzylamide (IV) [71074-45-8] derivatives of methotrexate (MTX) were synthesized from 4-amino-4-deoxy-N10-methylpteroic acid  [19741-14-1] and the appropriate blocked L-glutamic acid precursors with the aid of the peptide bond forming reagent di-Et phosphorocyanidate. The affinity of these side chain modified products for dihydrofolate reductase  [9002-03-3] from Lactobacillus casei and L1210 mouse leukemic cells was determined spectrophotometrically or by competitive radioligand binding assay, and their cytotoxicity was evaluated against L1210 leukemic cells in culture. The results provide continuing support for the view that the γ-terminal region of the MTX side chain is an attractive site for mol. modification of this anticancer agent. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Recommanded Product: (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

The Article related to methotrexate analog preparation anticancer, dihydrofolate reductase inhibitor methotrexate analog, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Recommanded Product: (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On July 15, 2018, Brear, Paul; North, Andrew; Iegre, Jessica; Hadje Georgiou, Kathy; Lubin, Alexandra; Carro, Laura; Green, William; Sore, Hannah F.; Hyvonen, Marko; Spring, David R. published an article.Reference of 3-Acetyldihydrofuran-2(3H)-one The title of the article was Novel non-ATP competitive small molecules targeting the CK2 α/β interface. And the article contained the following:

Increased CK2 levels are prevalent in many cancers. Combined with the critical role CK2 plays in many cell-signaling pathways, this makes it a prime target for down regulation to fight tumor growth. Herein, we report a fragment-based approach to inhibiting the interaction between CK2α and CK2β at the α-β interface of the holoenzyme. A fragment, CAM187, with an IC50 of 44μM and a mol. weight of only 257gmol-1 has been identified as the most promising compound Importantly, the lead fragment only bound at the interface and was not observed in the ATP binding site of the protein when co-crystallized with CK2α. The fragment-like mols. discovered in this study represent unique scaffolds to CK2 inhibition and leave room for further optimization. The experimental process involved the reaction of 3-Acetyldihydrofuran-2(3H)-one(cas: 517-23-7).Reference of 3-Acetyldihydrofuran-2(3H)-one

The Article related to preparation nonatp targeting ck2 alpha beta, ck2, fragment based drug discovery, protein-protein interaction, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Reference of 3-Acetyldihydrofuran-2(3H)-one

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On March 7, 1989, Kuefner, Ulrike; Lohrmann, Ute; Montejano, Yolanda D.; Vitols, Karin S.; Huennekens, F. M. published an article.Related Products of 53838-27-0 The title of the article was Carboxypeptidase-mediated release of methotrexate from methotrexate α-peptides. And the article contained the following:

Methotrexate (MTX) α-peptides containing representative neutral (alanine), acidic (aspartic acid), and basic (arginine) amino acids were synthesized by a regiospecific route. These peptides were hydrolyzed by carboxypeptidases to yield MTX and the amino acids. Pancreatic carboxypeptidase A (CP-A) hydrolyzed MTX-Ala and, at a much slower rate, MTX-Asp and MTX-Arg. MTX-Ala was also a substrate for pancreatic carboxypeptidase B (CP-B); marginal activity was observed with this enzyme and MTX-Arg. Human serum hydrolyzed only MTX-Arg; biphasic inhibition of this activity by 2-(mercaptomethyl)-3-(guanidinoethyl)thiopropionate was consistent with the known presence of 2 types of endogenous carboxypeptidase (CP-N). Cytotoxicity of the MTX peptides toward L1210 cells in culture was enhanced considerably in the presence of the appropriate carboxypeptidases. MTX-Ala was much less toxic than MTX (ID50 values of 2.0 × 10-6M and 2.4 × 10-8M, resp.), but in the presence of CP-A the ID50 of the peptide improved to 8.5 × 10-8M. Similar results were obtained with MTX-Asp/CP-A and MTX-Ala/CP-B combinations. MTX-Arg showed good cytotoxicity (ID50 of 5.0 × 10-8M), due to CP-N activity in the fetal bovine serum of the culture medium; inclusion of CP-B lowered the ID50 to that of MTX. Possible clin. uses of MTX peptides are discussed. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Related Products of 53838-27-0

The Article related to methotrexate peptide preparation cytotoxicity carboxypeptidase, antitumor methotrexate peptide prodrug preparation, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Related Products of 53838-27-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Volkov, G. U.; Boichuk, B. G. published an article in 1988, the title of the article was Kinetic features of the oxidative copolymerization of methacrylic esters with oligomeric piperylene rubber in a film.HPLC of Formula: 1985-51-9 And the article contains the following content:

The ratio (R) between consumption rates of double bonds and O was monitored during oxidative polymerization of piperylene rubber-dodecyl methacrylate (I) or – neopentyl glycol dimethacrylate (II) coatings to elucidate the roles of homopolymerization and copolymerization with O in this reaction. The R was ∼1-2 during almost entire period of polymerization, indicating that the homopolymerization somewhat prevailed over the copolymerization An increase in R toward the end of polymerization of coatings containing ≤35% I was attributed to morphol. changes that transfered the process into diffusion regime. A decrease in R in the beginning of polymerization of coatings containing II was ascribed to the decomposition of II associates The latter coatings showed a sharp increase in R toward the end of polymerization, due to increased consumption rate of vinyl bonds. The activation energies of oxidative polymerization processes were determined The experimental process involved the reaction of 2,2-Dimethylpropane-1,3-diyl bis(2-methylacrylate)(cas: 1985-51-9).HPLC of Formula: 1985-51-9

The Article related to oxidative polymerization piperylene rubber acrylate coating, kinetics oxidative polymerization piperylene rubber acrylate, Coatings, Inks, and Related Products: Curing Processes and Agents and other aspects.HPLC of Formula: 1985-51-9

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics